CME Presentations
CLL QI
Presentations
Cytogenetic Testing for Patients with CLL/SLL
Speakers: Nilanjan Ghosh, MD, PhD, Professor of Medicine and ChairDanielle Brander, MD, Assistant Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapy Duration: 30 minutes
Presented on: December 20, 2023
Guideline Recommendations for the Front-line Setting
Speakers: Nilanjan Ghosh, MD, PhD, Professor of Medicine and ChairDanielle Brander, MD, Assistant Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapy Duration: 30 minutes
Presented on: December 20, 2023
Guideline Recommendations for the Relapsed/Refractory Setting
Speakers: Matthew Davids, MD, MMSc, Director of Clinical Research and Associate Director of Chronic Lymphocytic Leukemia (CLL) Center, Division of LymphomaNicole Lamanna, MD, Professor of Medicine Duration: 30 minutes
Presented on: February 12, 2024
Patient Priorities for CLL Care
Speakers: Matthew Davids, MD, MMSc, Director of Clinical Research and Associate Director of Chronic Lymphocytic Leukemia (CLL) Center, Division of LymphomaNicole Lamanna, MD, Professor of Medicine Duration: 30 minutes
Presented on: February 12, 2024
Speakers
Nilanjan Ghosh, MD, PhD
Nilanjan Ghosh, MD, PhD
Professor of Medicine and Chair
Nilanjan Ghosh, MD, PhD is an attending physician, a professor of medicine, and chair of the Department of Hematologic Oncology and Blood Disorders at the Levine Cancer Institute, as well as a clinical professor of medicine at Wake Forest Baptist, all associated with Atrium Health. Board-certified in hematology-oncology (cancer and blood disorders), Dr. Ghosh specializes in treating lymphoma and chronic lymphocytic leukemia. He is the founder and serves as chief of the Lymphoma Division at Levine. His research interests include lymphoma, chronic lymphocytic leukemia, CAR T-cell therapy, stem-cell transplant, development of novel therapies, and overcoming disparities in healthcare.
Danielle Brander, MD
Danielle Brander, MD
Assistant Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapy
Danielle Brander, MD, is a graduate of Duke University School of Medicine. Dr. Brander completed her residency/fellowship, in the Department of Internal Medicine and trained in Hematology/Oncology. She is an Assistant Professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapy, an area in which she is a specialist, at the Duke Medical School. In addition, she is a member of the Duke Cancer Institute. Her main focus is on Chronic Lymphocytic Leukemia (CLL) and other slow growing or indolent Lymphomas. Dr. Brander would like patients to know that she understands that this is a new and different situation for them, and that this is a partnership for the long haul. She also wants them to know that she has compassion for what they are going through.
Matthew Davids, MD, MMSc
Matthew Davids, MD, MMSc
Director of Clinical Research and Associate Director of Chronic Lymphocytic Leukemia (CLL) Center, Division of Lymphoma
Matthew Davids, MD, MMSc, is an attending physician in the Division of Lymphoma at Harvard Medical School as well as an Associate Professor of Medicine. Also, he serves as the Director of Clinical Research as well as Associate Director of the CLL Center. Moreover, he attends the inpatient hematologic malignancies service at Brigham & Women’s Hospital. Dr. Davids has an active translational research program in CLL and non-Hodgkin lymphoma, focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of agents.
Nicole Lamanna, MD
Nicole Lamanna, MD
Professor of Medicine
Nicole Lamanna, MD serves as professor of medicine and director of the chronic lymphocytic leukemia (CLL) program in the hematologic malignancies section of the Hematology/Oncology Division at Columbia University Medical Center. Dr. Lamanna specializes in the treatment of adult patients with acute and chronic leukemias, with a focus on CLL. Her research focuses on the development of novel combination therapies, including immune-modulatory drugs, kinase inhibitors, Bcl-2 inhibitors, and monoclonal antibodies, as well as new agents in development for CLL. She is a staunch patient advocate and participates regularly in CLL patient advocacy groups to educate patients about their disease and treatment options.
CME Information
Patient Priorities for CLL Care
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC. in collaboration with CLL Society.
ACKNOWLEDGEMENT
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.RELEASE/EXPIRATION DATES
This activity was released on February 12, 2024 and is valid for 12 months. Requests for credit must be made no later than February 12, 2025.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based physicians and teams, including malignant hematologists or hematologic oncologists, medical oncologists, oncology nurses, nurse practitioners, physician assistants, nurses, and other members of the CLL care team.STATEMENT OF NEED/PROGRAM OVERVIEW
As targeted therapies have become the standard of care in chronic lymphocytic leukemia (CLL), it is increasingly important to refine therapy selection based on risk stratification. An in-depth analysis of community-based CLL practice patterns, registry data, and clinical guidelines can provide a benchmark for your own practice. Does your practice align with current evidence?
Hear from expert clinicians, Dr. Matthew Davids and Dr. Nicole Lamanna, as they explore current data and the patient and care-team factors that influence selection of therapy for CLL in the community setting. The panel will provide practical strategies to apply in your practice; which may can include improving timely testing, documentation, risk-stratification, treatment selection, and CLL management. Walk away with ready-to-implement actions to improve your team’s management of newly diagnosed and relapsed/refractory CLL.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Compare and contrast efficacy and safety data for guideline-recommended therapy options in the frontline and relapsed/recurrent settings
- Integrate targeted therapy into point-of-care decisions for patients with CLL
- Evaluate real-world patient-provider data to align on therapeutic goals, guideline-adherent practices, and delivery of quality care
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Matthew S. Davids, MD, MMSc Associate Professor of Medicine
Director of Clinical Research, Division of Lymphoma
Harvard Medical School
Dana-Farber Cancer InstituteConsulting Fee (e.g., Advisory Board): AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol-Myers Squibb, Eli Lilly, Genentech, Janssen, Merck, Ono Pharmaceuticals, Secura Bio, Takeda, TG Therapeutics
Contracted Research: AbbVie, Ascentage Pharma, AstraZeneca, Genentech, Novartis, Secura Bio, TG Therapeutics
Honoraria: Aptitude Health, Curio ScienceNicole Lamanna, MD
Professor of Medicine
Director of Chronic Lymphocytic Leukemia Program
Leukemia Service
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center/New York-PresbyterianConsulting Fee (e.g., Advisory Board): Abbvie, AstraZeneca, Adaptive, Allogene, Beigene, EliLilly/Loxo, Genmab, Janssen/Pharmacyclics
Contracted Research (Principal Investigators must provide information, even if received by the institution): Abbvie, AstraZeneca, Beigene, EliLily/Loxo, Genmab, MingSight, Oncternal, Octapharma
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact, OMedLive, at 877-394-1306 or at Support@OMedLive.com.
Guideline Recommendations for the Relapsed/Refractory Setting
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC. in collaboration with CLL Society.
ACKNOWLEDGEMENT
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.RELEASE/EXPIRATION DATES
This activity was released on February 12, 2024 and is valid for 12 months. Requests for credit must be made no later than February 12, 2025.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based physicians and teams, including malignant hematologists or hematologic oncologists, medical oncologists, oncology nurses, nurse practitioners, physician assistants, nurses, and other members of the CLL care team.STATEMENT OF NEED/PROGRAM OVERVIEW
As targeted therapies have become the standard of care in chronic lymphocytic leukemia (CLL), it is increasingly important to refine therapy selection based on risk stratification. An in-depth analysis of community-based CLL practice patterns, registry data, and clinical guidelines can provide a benchmark for your own practice. Does your practice align with current evidence?
Hear from expert clinicians, Dr. Matthew Davids and Dr. Nicole Lamanna, as they explore current data and the patient and care-team factors that influence selection of therapy for CLL in the community setting. The panel will provide practical strategies to apply in your practice; which may can include improving timely testing, documentation, risk-stratification, treatment selection, and CLL management. Walk away with ready-to-implement actions to improve your team’s management of newly diagnosed and relapsed/refractory CLL.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Compare and contrast efficacy and safety data for guideline-recommended therapy options in the frontline and relapsed/recurrent settings
- Integrate targeted therapy into point-of-care decisions for patients with CLL
- Evaluate real-world patient-provider data to align on therapeutic goals, guideline-adherent practices, and delivery of quality care
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Matthew S. Davids, MD, MMSc Associate Professor of Medicine
Director of Clinical Research, Division of Lymphoma
Harvard Medical School
Dana-Farber Cancer InstituteConsulting Fee (e.g., Advisory Board): AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol-Myers Squibb, Eli Lilly, Genentech, Janssen, Merck, Ono Pharmaceuticals, Secura Bio, Takeda, TG Therapeutics
Contracted Research: AbbVie, Ascentage Pharma, AstraZeneca, Genentech, Novartis, Secura Bio, TG Therapeutics
Honoraria: Aptitude Health, Curio ScienceNicole Lamanna, MD
Professor of Medicine
Director of Chronic Lymphocytic Leukemia Program
Leukemia Service
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center/New York-PresbyterianConsulting Fee (e.g., Advisory Board): Abbvie, AstraZeneca, Adaptive, Allogene, Beigene, EliLilly/Loxo, Genmab, Janssen/Pharmacyclics
Contracted Research (Principal Investigators must provide information, even if received by the institution): Abbvie, AstraZeneca, Beigene, EliLily/Loxo, Genmab, MingSight, Oncternal, Octapharma
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact, OMedLive, at 877-394-1306 or at Support@OMedLive.com.
Guideline Recommendations for the Front-line Setting
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC. in collaboration with CLL Society and the Leukemia and Lymphoma Society.
ACKNOWLEDGEMENT
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.RELEASE/EXPIRATION DATES
This activity was released on December 20, 2023 and is valid for 14 months. Requests for credit must be made no later than February 12, 2025.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based physicians and teams, including malignant hematologists or hematologic oncologists, medical oncologists, oncology nurses, nurse practitioners, physician assistants, nurses, and other members of the CLL care team.STATEMENT OF NEED/PROGRAM OVERVIEW
As targeted therapies have become the standard of care in chronic lymphocytic leukemia (CLL), it is increasingly important to refine therapy selection based on risk stratification. An in-depth analysis of community-based CLL practice patterns, registry data, and clinical guidelines can provide a benchmark for your own practice. Does your practice align with current evidence?
Hear from expert clinicians, Dr. Danielle Brander and Dr. Nilanjan Ghosh, as they explore current data and the patient and care-team factors that influence selection of therapy for CLL in the community setting. The panel will provide practical strategies to apply in your practice; which may can include improving timely testing, documentation, risk-stratification, treatment selection, and CLL management. Walk away with ready-to-implement actions to improve your team’s management of newly diagnosed and relapsed/refractory CLL.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Apply the findings from the informCLL study as they relate to prognostic and cytogenetic testing in patients with CLL/SLL
- Compare and contrast efficacy and safety data for guideline-recommended therapy options in the frontline and relapsed/recurrent settings
- Integrate targeted therapy into point-of-care decisions for patients with CLL
- Evaluate real-world patient-provider data to align on therapeutic goals, guideline-adherent practices, and delivery of quality care
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Danielle M. Brander, MD Assistant Professor of Medicine
Director, CLL & Lymphoma Clinical Research Program
Duke Cancer InstituteConsulting Fee (e.g., Advisory Board): AbbVie, Pharmacyclics
Contracted Research: AbbVie, ArQule/Merck, Ascentage, AstraZeneca/Acerta, BeiGene, Catapult, DTRM, Genentech, Juno/Celgene/BMS, MEI Pharma, NeWave, Novartis, Pharmacyclics, TG Therapeutics
Other: InformCLL registry steering committee (Pharmacyclics), CORE registry steering committee (AbbVie)Nilanjan Ghosh, MD, PhD, FACP
Kerry and Simone Vickar Family Foundation Endowed Chair
Chair, Department of Hematologic Oncology and Blood Disorders
Chief, Lymphoma Division
Levine Cancer Institute, Atrium Health, Charlotte, NC
Clinical Professor of Internal Medicine
Wake Forest University School of MedicineConsulting Fee (e.g., Advisory Board): Seagen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, Beigene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics
Contracted Research (Principal Investigators must provide information, even if received by the institution): TG Therapeutics, Genentech/Roche, Bristol Myers Squibb, Gilead, Morphosys, AbbVie, Pharmacyclics
Honoraria: Seagen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, Beigene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics
Speakers' Bureau: AstraZeneca
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact, OMedLive, at 877-394-1306 or at Support@OMedLive.com.
Cytogenetic Testing for Patients with CLL/SLL
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC. in collaboration with CLL Society and the Leukemia and Lymphoma Society.
ACKNOWLEDGEMENT
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.RELEASE/EXPIRATION DATES
This activity was released on December 20, 2023 and is valid for 14 months. Requests for credit must be made no later than February 12, 2025.TARGET AUDIENCE
The educational design of this activity addresses the needs of community-based physicians and teams, including malignant hematologists or hematologic oncologists, medical oncologists, oncology nurses, nurse practitioners, physician assistants, nurses, and other members of the CLL care team.STATEMENT OF NEED/PROGRAM OVERVIEW
As targeted therapies have become the standard of care in chronic lymphocytic leukemia (CLL), it is increasingly important to refine therapy selection based on risk stratification. An in-depth analysis of community-based CLL practice patterns, registry data, and clinical guidelines can provide a benchmark for your own practice. Does your practice align with current evidence?
Hear from expert clinicians, Dr. Danielle Brander and Dr. Nilanjan Ghosh, as they explore current data and the patient and care-team factors that influence selection of therapy for CLL in the community setting. The panel will provide practical strategies to apply in your practice; which may can include improving timely testing, documentation, risk-stratification, treatment selection, and CLL management. Walk away with ready-to-implement actions to improve your team’s management of newly diagnosed and relapsed/refractory CLL.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Apply the findings from the informCLL study as they relate to prognostic and cytogenetic testing in patients with CLL/SLL
- Compare and contrast efficacy and safety data for guideline-recommended therapy options in the frontline and relapsed/recurrent settings
- Integrate targeted therapy into point-of-care decisions for patients with CLL
- Evaluate real-world patient-provider data to align on therapeutic goals, guideline-adherent practices, and delivery of quality care
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Danielle M. Brander, MD Assistant Professor of Medicine
Director, CLL & Lymphoma Clinical Research Program
Duke Cancer InstituteConsulting Fee (e.g., Advisory Board): AbbVie, Pharmacyclics
Contracted Research: AbbVie, ArQule/Merck, Ascentage, AstraZeneca/Acerta, BeiGene, Catapult, DTRM, Genentech, Juno/Celgene/BMS, MEI Pharma, NeWave, Novartis, Pharmacyclics, TG Therapeutics
Other: InformCLL registry steering committee (Pharmacyclics), CORE registry steering committee (AbbVie)Nilanjan Ghosh, MD, PhD, FACP
Kerry and Simone Vickar Family Foundation Endowed Chair
Chair, Department of Hematologic Oncology and Blood Disorders
Chief, Lymphoma Division
Levine Cancer Institute, Atrium Health, Charlotte, NC
Clinical Professor of Internal Medicine
Wake Forest University School of MedicineConsulting Fee (e.g., Advisory Board): Seagen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, Beigene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics
Contracted Research (Principal Investigators must provide information, even if received by the institution): TG Therapeutics, Genentech/Roche, Bristol Myers Squibb, Gilead, Morphosys, AbbVie, Pharmacyclics
Honoraria: Seagen, TG Therapeutics, AstraZeneca, Phamacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, Beigene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics
Speakers' Bureau: AstraZeneca
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact, OMedLive, at 877-394-1306 or at Support@OMedLive.com.
